Sangamo Therapeutics, Inc. SGMO Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sangamo Therapeutics, Inc. SGMO

SGMO 0.578

-3.6%

Nov 3 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: bob zagorin who wrote (283)	11/11/2008 10:37:34 AM
From: bob zagorin	of 368

Recommendations story about SGMO from Cantor After Sangamo reported Phase II data that Cantor views as positive for its SB-509-601 treatment for diabetes neuropathy, Cantor expects the drug to advance towards a pivotal trial and they view any drops in the stock as buying opportunities. The firm reiterated a Buy rating.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next